Publications by authors named "Hedy Hollyfield"
Clin Pharmacol Drug Dev
January 2018
Article Synopsis
- Lapatinib is used to treat metastatic breast cancers that over-express HER2, but current tablets require taking up to six large pills, prompting the development of a powder for oral suspension.
- A study was conducted to compare the powder and the tablets in advanced cancer patients using a two-period crossover design, which allows for a more efficient trial with fewer subjects needed.
- The study showed that the powder was bioequivalent to the tablets, fulfilling the criteria for absorption rates and safety, meaning patients can safely switch to the easier-to-take powder formulation.
